Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Company Deals

Danaher to Acquire Masimo for $9.9B – Expands Diagnostics Platform with Pulse Oximetry Leader

Fineline Cube Feb 26, 2026
Company Deals

Novo Nordisk Partners with Vivtex on $2.1B Oral Biologics Deal – Targets Obesity and Diabetes Delivery Innovation

Fineline Cube Feb 26, 2026
Company Deals

GSK to Acquire 35Pharma for $950M – Adds Potential Best‑in‑Class PAH Asset HS235

Fineline Cube Feb 26, 2026
Company Deals

Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer

Fineline Cube Feb 25, 2026
Policy / Regulatory

NMPA Approves 76 Innovative Medical Devices in 2025 – 17% YoY Growth Driven by AI and Priority Review Surge

Fineline Cube Feb 26, 2026
Company Drug

Fosun Pharma’s Luvometinib Cleared for Phase II NSCLC Combination Trial – MEK Inhibitor Plus Anlotinib Targets KRAS Mutations

Fineline Cube Feb 26, 2026
Company Drug

3SBio’s SSGJ-611 NDA Accepted by NMPA – Anti-IL-4Rα mAb Targets Moderate-to-Severe Atopic Dermatitis

Fineline Cube Feb 26, 2026
Company Drug

Amgen’s Bkemv Becomes First Biosimilar to Challenge AstraZeneca’s Soliris with FDA Approval

Fineline Cube May 30, 2024

Amgen Inc. (NASDAQ: AMGN), a leading biopharmaceutical company, has been granted regulatory approval by the...

Company Drug

Full-Life Technologies Receives FDA Green Light for ²²⁵Ac-FL-020 Clinical Study in mCRPC

Fineline Cube May 30, 2024

Full-Life Technologies Ltd, a globally integrated radiotherapeutics company with a presence in Belgium, Germany, and...

Company Deals Medical Device

Jiangxi Rimag Group Sets IPO Price Range for Hong Kong Debut, Aims to Raise Up to USD 2.15 per Share

Fineline Cube May 30, 2024

Jiangxi Rimag Group Co., Ltd, a leading medical imaging services provider based in China, has...

Company Deals

IVD Medical Holding Ltd Enters Non-Binding MoU with Chinese Chemiluminescence IVD Company for Potential Collaboration

Fineline Cube May 30, 2024

IVD Medical Holding Ltd (HKG: 1931), a leading in vitro diagnostic (IVD) company based in...

Company Deals

BMS Strikes Deal with Prothena for Potential Disease-Modifying Neurology Drug PRX019

Fineline Cube May 30, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) has executed an exclusive global licensing agreement with Prothena...

Company Medical Device

Sino Medical Sciences’ Innovative Drug-Coated Stent System Accepted for NMPA Review

Fineline Cube May 29, 2024

Sino Medical Sciences Technology Inc. (SHA: 688108), a China-based medical technology company, has announced that...

Company Deals

Gilead Partners with Cartography Biosciences to Develop Therapies for Triple-Negative Breast Cancer

Fineline Cube May 29, 2024

Gilead Sciences (NASDAQ: GILD) has entered into a collaboration agreement with Cartography Biosciences, a US-based...

Company Deals

Sanofi Partners with Bluecrux to Enhance Supply Chain with AI Technologies

Fineline Cube May 29, 2024

Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, is enhancing its supply chain strategy with...

Company Deals

Bio-Thera Solutions Partners with STADA for European Commercialization of Golimumab Biosimilar

Fineline Cube May 29, 2024

Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced a licensing...

Company Deals

Roche Extends Long-Standing Partnership with Hitachi High-Tech to Innovate Diagnostic Solutions

Fineline Cube May 29, 2024

Roche (SWX: RO), a major Swiss pharmaceutical company, has renewed its 46-year partnership with Japan’s...

Company Deals

Asahi Kasei Moves to Fully Acquire Swedish Rare Disease Biopharma Calliditas in All-Cash Deal

Fineline Cube May 29, 2024

Japan’s Asahi Kasei Corporation (TYO: 3407) has announced an all-cash offer to fully acquire the...

Company Drug

Alphamab Oncology’s KN046 Misses Primary Endpoint in Phase III Pancreatic Cancer Study

Fineline Cube May 29, 2024

Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has announced disappointing results from...

Company Deals

3SBio Secures License for Semaglutide Biosimilar from Hybio Pharmaceutical

Fineline Cube May 29, 2024

3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, has announced a licensing agreement...

Policy / Regulatory

China Unveils Comprehensive Plan to Tackle Unhealthy Practices in Pharma and Healthcare

Fineline Cube May 28, 2024

The National Health Commission (NHC), National Healthcare Security Administration (NHSA), National Medical Products Administration (NMPA),...

Company Deals

ChemPartner and Meta Bright to Jointly Develop a Pharmaceutical and Biotech Hub in Malaysia

Fineline Cube May 28, 2024

ChemPartner Pharmatech Co., Ltd (SHE: 300149), a biopharmaceutical company based in China, and Meta Bright...

Company Drug

Boan Biotech’s Dulaglutide Biosimilar Accepted for Review by China’s CDE

Fineline Cube May 28, 2024

Boan Biotech (HKG: 6955), a biopharmaceutical company based in China, has announced that the Center...

Company Drug

Hinova Pharmaceuticals to Present Phase I Data for PROTAC Drug HP518 at ASCO 2024

Fineline Cube May 28, 2024

Hinova Pharmaceuticals (SHA: 688302), a biopharmaceutical company based in China, is poised to present data...

Company Drug

Henlius Biotech’s Biosimilar Rituximab Receives First Overseas Marketing Approval from Peru

Fineline Cube May 28, 2024

Shanghai Henlius Biotech Co., Ltd (HKG: 2696), a biopharmaceutical company based in China, has announced...

Company Drug

Hotgen Biotech Receives FDA Approval to Begin Clinical Trials for Acute Myocardial Infarction Drug

Fineline Cube May 28, 2024

Hotgen Biotech Co., Ltd (SHA: 688068), a biopharmaceutical company based in China, has announced that...

Company Drug

Innovent Biologics’ Picankibart Achieves Positive Results in Phase III Psoriasis Trial

Fineline Cube May 28, 2024

Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, has announced the successful...

Posts pagination

1 … 314 315 316 … 627

Recent updates

  • SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement
  • NMPA Approves 76 Innovative Medical Devices in 2025 – 17% YoY Growth Driven by AI and Priority Review Surge
  • Fosun Pharma’s Luvometinib Cleared for Phase II NSCLC Combination Trial – MEK Inhibitor Plus Anlotinib Targets KRAS Mutations
  • NMPA CDE Opens Public Consultation for 104th Reference Listed Drugs Catalog – 63 Specifications Under Review
  • Danaher to Acquire Masimo for $9.9B – Expands Diagnostics Platform with Pulse Oximetry Leader
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Policy / Regulatory

NMPA Approves 76 Innovative Medical Devices in 2025 – 17% YoY Growth Driven by AI and Priority Review Surge

Company Drug

Fosun Pharma’s Luvometinib Cleared for Phase II NSCLC Combination Trial – MEK Inhibitor Plus Anlotinib Targets KRAS Mutations

Policy / Regulatory

NMPA CDE Opens Public Consultation for 104th Reference Listed Drugs Catalog – 63 Specifications Under Review

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.